This is Alzinova
Alzinova AB is a Swedish clinical-stage company specializing in the treatment of Alzheimer’s disease – one of the major health scourges, without effective treatment options. The Company’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the neurotoxic amyloid-β oligomers involved in the onset and progression of the disease.
